Xenon Pharmaceuticals Inc. (XENE) NASDAQ

39.06

+1.08(+2.84%)

Updated at September 29 04:00PM

Currency In USD

Xenon Pharmaceuticals Inc.

Address

3650 Gilmore Way

Burnaby, BC V5G 4W8

Canada

Phone

16044843300

Sector

Healthcare

Industry

Biotechnology

Employees

316

First IPO Date

November 05, 2014

Key Executives

NameTitlePayYear Born
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.President, Chief Executive Officer & Director1.18M1976
Dr. James R. Empfield Ph.D.Executive Vice President of Drug Discovery323,4281961
Dr. Robin P. Sherrington Ph.D.Executive Vice President of Strategy & Innovation587,0281961
Ms. Andrea DiFabio J.D.Chief Legal Officer & Corporate Secretary682,2521968
Ms. Sherry Aulin C.A., CPAChief Financial Officer742,6501983
Dr. Christopher John Kenney M.D.Chief Medical Officer774,7021971
Ms. Shelley McClCoskey B.A.Executive Vice President of Human Resources01960
Dr. Matthew D. Ronsheim Ph.D.Chief Operating Officer01972

Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.